Live price temporarily unavailable.
Price history
Avnet (AVT) is a Information Technology company in the Russell 1000. Latest news and coverage below.
Avnet revenue & net income history (FY2017–FY2026)
RevenueNet income
| FY2017Jul 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jul 2021 | FY2022Jul 2022 | FY2023Jul 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $17.4B | $19.0B | $19.5B | $17.6B | $19.5B | $24.3B | $26.5B | $23.8B | $22.2B | $27.6B |
| Growth (year over year) | +4.2% | +9.2% | +2.5% | −9.7% | +10.8% | +24.4% | +9.2% | −10.5% | −6.6% | +24.5% |
| Gross profit | $2.37B | $2.53B | $2.49B | $2.06B | $2.24B | $2.97B | $3.18B | $2.77B | $2.38B | $2.88B |
| Gross margin | 13.6% | 13.3% | 12.7% | 11.7% | 11.5% | 12.2% | 12.0% | 11.6% | 10.7% | 10.4% |
| Operating income | $443.7M | $209.2M | $365.9M | −$4.63M | $281.4M | $939.0M | $1.19B | $844.4M | $514.3M | $724.8M |
| Operating margin | 2.5% | 1.1% | 1.9% | −0.0% | 1.4% | 3.9% | 4.5% | 3.6% | 2.3% | 2.6% |
| Net income | $525.3M | −$156.4M | $176.3M | −$31.1M | $193.1M | $692.4M | $770.8M | $498.7M | $240.2M | $334.4M |
| Net margin | 3.0% | −0.8% | 0.9% | −0.2% | 1.0% | 2.8% | 2.9% | 2.1% | 1.1% | 1.2% |
| EPS (diluted) | $4.08 | −$1.30 | $1.59 | −$0.31 | $1.93 | $6.94 | $8.26 | $5.43 | $2.75 | $4.01 |
| Balance sheet | ||||||||||
| Cash and equivalents | $836.4M | $621.1M | $546.1M | $477.0M | $199.7M | $153.7M | $288.2M | $310.9M | $192.4M | $155.4M |
| Total assets | $9.70B | $9.60B | $8.56B | $8.11B | $8.93B | $10.4B | $12.5B | $12.2B | $12.1B | $15.4B |
| Total liabilities | $4.52B | $4.91B | $4.42B | $4.38B | $4.84B | $6.20B | $7.73B | $7.28B | $7.11B | $10.4B |
| Long-term debt | $1.73B | $1.49B | $1.42B | $1.42B | $1.19B | $1.44B | $2.99B | $2.41B | $2.57B | $2.48B |
| Shareholders' equity | $5.18B | $4.69B | $4.14B | $3.73B | $4.08B | $4.19B | $4.75B | $4.93B | $5.01B | $5.02B |
| Cash flow | ||||||||||
| Operating cash flow | −$368.7M | $253.5M | $534.8M | $730.2M | $90.9M | −$219.3M | −$713.7M | $690.0M | $724.5M | −$280.9M |
| Capital expenditure | $120.4M | $155.9M | $122.7M | $73.5M | $50.4M | $48.9M | $194.7M | $226.5M | $147.5M | $73.6M |
| Free cash flow | −$489.1M | $97.6M | $412.1M | $656.7M | $40.6M | −$268.2M | −$908.4M | $463.5M | $577.0M | −$354.5M |
| Dividends paid | $88.7M | $88.3M | $87.2M | $84.0M | $84.3M | $98.5M | $106.3M | $112.0M | $113.3M | $114.4M |
| Share buybacks | $275.9M | $323.5M | $568.7M | $237.8M | — | $184.4M | $221.7M | $162.7M | $303.5M | $138.3M |
RevenueNet income
| Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.60B | $5.66B | $5.32B | $5.62B | $5.90B | $6.32B | $7.12B | $8.30B |
| Growth (year over year) | −11.5% | −8.7% | −6.0% | +1.0% | +5.3% | +11.6% | +33.9% | +47.7% |
| Gross profit | $607.4M | $596.1M | $587.9M | $593.7M | $614.8M | $663.0M | $739.1M | $865.0M |
| Gross margin | 10.8% | 10.5% | 11.1% | 10.6% | 10.4% | 10.5% | 10.4% | 10.4% |
| Operating income | $142.2M | $155.3M | $143.3M | $73.5M | $142.0M | $146.2M | $205.5M | $231.0M |
| Operating margin | 2.5% | 2.7% | 2.7% | 1.3% | 2.4% | 2.3% | 2.9% | 2.8% |
| Net income | $59.0M | $87.3M | $87.9M | $6.09M | $51.7M | $61.7M | $94.3M | $126.6M |
| Net margin | 1.1% | 1.5% | 1.7% | 0.1% | 0.9% | 1.0% | 1.3% | 1.5% |
| EPS (diluted) | $0.66 | $0.99 | $1.01 | $0.09 | $0.61 | $0.75 | $1.14 | $1.51 |
| Balance sheet | ||||||||
| Cash and equivalents | $267.5M | $172.1M | $188.9M | $192.4M | $175.5M | $286.5M | $202.4M | $155.4M |
| Total assets | $12.6B | $11.9B | $11.7B | $12.1B | $12.4B | $13.2B | $13.5B | $15.4B |
| Total liabilities | $7.56B | $7.10B | $6.83B | $7.11B | $7.57B | $8.22B | $8.54B | $10.4B |
| Long-term debt | $2.43B | $2.57B | $2.49B | $2.57B | $2.80B | $2.47B | $2.47B | $2.48B |
| Shareholders' equity | $5.04B | $4.84B | $4.88B | $5.01B | $4.85B | $4.94B | $4.95B | $5.02B |
| Cash flow | ||||||||
| Operating cash flow | $106.3M | $337.8M | $140.9M | $139.5M | −$144.6M | $208.2M | −$53.8M | −$290.7M |
| Capital expenditure | $31.8M | $29.4M | $26.7M | $59.6M | $24.6M | $15.4M | $16.9M | $16.8M |
| Free cash flow | $74.5M | $308.5M | $114.1M | $79.9M | −$169.2M | $192.9M | −$70.7M | −$307.5M |
| Dividends paid | $28.9M | $28.6M | $28.2M | $27.7M | $28.5M | $28.5M | $28.7M | $28.7M |
| Share buybacks | $100.0M | $52.2M | $101.3M | $50.0M | $138.3M | $0 | $0 | $0 |
From Avnet's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Avnet
Avnet, Inc. is a distributor of electronic components headquartered in Tempe, Arizona, named after Charles Avnet, who founded the company in 1921. After its start on Manhattan's Radio Row, the company was incorporated in 1955 and began trading on the New York Stock Exchange in 1961. On May 8, 2018, Avnet changed stock markets to Nasdaq, trading under the same ticker AVT.
- Headquarters
- Tempe, Arizona From SEC filings, Oct 2026
Recent News (2)
-
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites
-
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites
More Information Technology stocks
- ALAB Astera Labs
- ARM Arm Holdings
- ASML ASML Holding
- MRVL Marvell Technology
- AAPL Apple Inc.
- ACN Accenture
- ADBE Adobe Inc.
- ADI Analog Devices